Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-01-04 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE CLINICAL TRIAL OF SELF-DEVELOPED CLASS I NEW DRUG OT-202 IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the enrollment of the first patient in a clinical trial for a self-developed new drug OT-202. It is an update on business progress and clinical development rather than a financial report, regulatory filing, or meeting-related document. The text is relatively short (3514 characters) and does not contain financial statements, voting results, or management changes. It is an announcement of a business development event, which fits best under the category of a general regulatory announcement or miscellaneous update. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-01-04 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Ocumension Therapeutics. It details the issuance of new ordinary shares under a share award scheme, including the number of shares issued, dates, and confirmations by the board. The document references compliance with listing rules of the Stock Exchange of Hong Kong and provides detailed information about share issuance but does not contain financial statements or earnings data. This type of document is an official announcement regarding changes in share capital, specifically a share issue. It is not a full financial report, earnings release, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length (7599 characters) and detailed content support this classification with high confidence.
2021-12-21 English
(I) AMENDMENTS TO THE SCHEME RULES OF THE 2021 SHARE AWARD SCHEME&#x3b; (II) APPOINTMENT OF TRUSTEE FOR ADMINISTERING THE 2021 SHARE AWARD SCHEME&#x3b; AND (III) PLAN TO SATISFY PART OF THE AWARD SHAR
Regulatory Filings Classification · 95% confidence The document is an announcement from Ocumension Therapeutics regarding amendments to the rules of their 2021 Share Award Scheme, appointment of a trustee for administering the scheme, and plans related to satisfying award shares through on-market transactions. It discusses governance and administrative changes related to a share award plan, including details about the trustee appointment and share acquisition methods. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full report but an announcement of changes and plans related to share awards and trustee appointment. This fits best under a regulatory announcement category related to share schemes and governance but not a full governance report or remuneration report. Given the content and nature, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit other specific categories like MANG (management changes) or DEF 14A (remuneration). The document is substantive and over 11,000 characters, so it is not a mere report publication announcement (RPA).
2021-12-03 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities, specifically focusing on the issuer's share capital, issued shares, share options, warrants, and other related share issuance activities. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to compliance with listing rules. The document does not contain financial statements or earnings data but rather regulatory disclosures about share capital changes and securities movements for the month ended 30 November 2021. This type of document is a regulatory filing related to share capital movements and securities issuance, typically submitted to the stock exchange as part of ongoing compliance. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update, as it is more of a regulatory compliance report on share movements. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-12-03 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Ocumension Therapeutics. It details the exercise of share options by a director, the number of shares issued, issue price, and confirmations related to the authorization and compliance with listing rules. The document references specific listing rules from the Stock Exchange of Hong Kong and provides detailed information about share capital changes. This type of document is a formal announcement regarding changes in the company's capital structure, specifically share issues due to option exercises. It is not a full financial report, earnings release, or management discussion, but rather a regulatory disclosure about share capital changes. Therefore, it fits best under the category 'Share Issue/Capital Change' (SHA). The document length (7448 characters) and content confirm it is a substantive disclosure, not merely an announcement of a report or a certification. Confidence is high due to the clear focus on share capital changes and compliance with listing rules.
2021-11-16 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities for a listed issuer, specifically focusing on share capital, issued shares, share options, warrants, and other share-related movements. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to securities issuance and compliance with listing rules. The content is regulatory in nature, reporting on share capital and share issuance activities, but it is not an announcement of a new share issue or capital change per se, nor is it a simple announcement or a brief factsheet. It is a formal regulatory filing reporting monthly movements in securities and share capital, consistent with regulatory compliance requirements. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it does not fit the more specific categories like Share Issue/Capital Change (SHA) which typically covers announcements of new share issues or capital changes, but rather a comprehensive regulatory return on share movements.
2021-11-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.